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Purpose: To evaluate the diagnostic performance of imaging fea-
tures of gadoxetic acid–enhanced magnetic resonance 
(MR) imaging to differentiate among hepatocellular ade-
noma (HCA) subtypes by using the histopathologic results 
of the new immunophenotype and genotype classification 
and to correlate the enhancement pattern on the hepa-
tobiliary phase (HBP) with the degrees of expression of 
organic anion transporting polypeptide (OATP1B1/3), 
multidrug resistance-associated protein 2 (MRP) (MRP2), 
and MRP 3 (MRP3) transporters.
Materials and 
Methods:
This retrospective study was approved by the institu-
tional review board, and the requirement for informed 
consent waived. MR imaging findings of 29 patients with 
43 HCAs were assessed by two radiologists independently 
then compared with the histopathologic analysis as the 
standard of reference. Receiver operating characteristic 
curves and Spearman rank correlation coefficient were 
used to test the diagnostic performance of gadoxetic 
acid–enhanced MR imaging features, which included the 
retention or washout at HBP and degree of transporter 
expression. Interreader agreement was assessed by using 
the k statistic with 95% confidence interval.
Results: The area under the curve for the diagnosis of inflamma-
tory HCA was 0.79 (95% confidence interval: 0.64, 0.90); 
for the steatotic type, it was 0.90 (95% confidence inter-
val: 0.77, 0.97); and for the b-catenin type, it was 0.87 
(95% confidence interval: 0.74, 0.95). There were no 
imaging features that showed a significant statistical cor-
relation for the diagnosis of unclassified HCAs. On immu-
nohistochemical staining, OATP1B1/3 expression was the 
main determinant for the retention, whereas MRP3 was 
the key determinant for washout of gadoxetic acid at HBP 
(P , .001). MRP2 appeared to have no role.
Conclusion: Gadoxetic acid–enhanced MR imaging features may sug-
gest the subtype of HCA. The degree of OATP1B1/3 and 
MRP3 expression correlated statistically with gadoxetic 
acid retention and washout, respectively, in the HBP.
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Hepatocellular adenoma (HCA) poses a diagnostic challenge be-cause its imaging appearance and 
enhancement patterns at cross-sec-
tional imaging, including computed 
tomographic (CT) and magnetic reso-
nance (MR) imaging, are variable (1–
4). The histopathologic work-up may 
be an equal challenge (5,6). Recently, 
HCA was subdivided into four types ac-
cording to the Bordeaux group by using 
genotype and phenotype classification 
(7–9). Because HCAs have diverse clin-
ical courses on the basis of their sub-
type, medical versus surgical manage-
ment may rely on an accurate imaging 
classification (10). The value of MR 
Implication for Patient Care
 n Noninvasive gadoxetic acid–
enhanced MR classification of 
HCA subgroups on the basis of 
the morphologic features and 
enhancement pattern is impor-
tant because it substantially influ-
ences management: for steatotic, 
unclassified, and inflammatory 
HCAs that do not exceed 5 cm in 
diameter or that do not grow, 
follow-up is sufficient; however, 
surgical resection is indicated if 
any of these lesions markedly 
increases in size, and surgical 
resection is the treatment of 
choice for any b-catenin HCA, 
independent of size.
Advances in Knowledge
 n We found a statistically signifi-
cant difference in the enhance-
ment pattern of gadoxetic acid 
among the four subtypes of he-
patocellular adenomas (HCAs) (P 
= .001); at the hepatobiliary 
phase (HBP), all steatotic and 
unclassified HCAs showed wash-
out of contrast media, while six 
of 21 (39%) inflammatory and 
five of six (83%) of b-catenin 
HCAs retained contrast media at 
20 minutes.
 n All tumors that showed equivocal 
or increased expression of or-
ganic anion transporting polypep-
tide (OATP) (OATP1B1/3) 
showed gadoxetic acid retention 
on HBP images (11 of 11 
[100%]), while tumors that 
showed decreased or no expres-
sion of OATP1B1/3 tended to 
show contrast agent washout on 
HBP images (21 of 32 [66%]) (P 
, .001).
 n All tumors that showed 
decreased or no expression of 
multidrug resistance–associated 
protein 3 (MRP) (MRP3) showed 
contrast-media retention on HBP 
images (11 of 11 [100%]), while 
tumors that showed equivalent or 
increased expression of MRP3 
tended to show gadoxetic acid 
washout on HBP images (15 of 
32 [47%]) (P = .008).
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imaging to distinguish between these 
subgroups was described in some re-
cent publications on the basis of specific 
features and contrast agent–enhance-
ment pattern (1,4,11,12). In particular, 
in the hepatobiliary phase (HBP) of MR 
imaging after administration of the con-
trast agent (ie, 20 minutes after the ad-
ministration of gadoxetic acid [Primov-
ist or Eovist; Bayer Healthcare, Berlin, 
Germany]), the majority of HCAs show 
washout and appear hypointense to the 
surrounding liver tissue (13,14). In-
creasingly, the literature (15–18) con-
tains reports of HCA nodules that show 
incomplete washout or even retention 
of gadoxetic acid during the HBP. Some 
theories suggest that these different en-
hancement patterns could be related to 
the subtype of the adenoma and sub-
sequently the amount and location of 
different transporter proteins, such as 
organic anion transporting polypeptide 
(OATP) 1B1/3 (OATP1B1/3) and mul-
tidrug resistance–associated protein 2 
(MRP) (MRP 2) and 3 (MRP3), which 
mediate the uptake and canalicular or 
basolateral excretion of gadoxetic acid 
during the HBP, respectively (19,20).
The expression of these trans-
porters and their role in contrast-
material uptake after the injection of 
gadoxetic acid underwent pathologic 
and radiologic study, but only in HCCs 
within the context of liver cirrhosis 
(21–23). To our knowledge, the role 
of the three key hepatobiliary trans-
porters was not systematically studied 
in patients with HCAs.
The purpose of our study was two-
fold: to evaluate the diagnostic perfor-
mance of imaging features of gadoxetic 
acid–enhanced MR imaging to distin-
guish between the four HCA subtypes 
by using the histopathologic results ac-
cording to the new immunophenotype 
and genotype classification, described 
by the Bordeaux group (7,10), as the 
standard of reference, and to correlate 
the retention or washout on the HBP 
phase with the degree of expression of 




Retrospective data collection and 
analysis were approved by the ethics 
review boards of the two participating 
hospitals; the requirement for informed 
consent was waived. We enrolled 29 
patients with 43 HCA lesions. These 
patients came from the institutional 
databases between 2007 and 2013. 
We included only those patients who 
underwent gadoxetic acid–enhanced 
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MR imaging and in whom we obtained 
pathologic proof of the diagnosis in one 
or more lesions, either after surgery 
(21 patients with 35 lesions) or after 
CT- or ultrasonographically guided bi-
opsy (eight patients with eight lesions). 
A study coordinator (D.F., a radiologist 
with 6 years of experience) was aware 
of which nodule or nodules underwent 
pathologic verification with MR images 
of patients with multiple HCAs. The 
MR findings of these nodules were in-
dependently evaluated by two radiolo-
gists and subsequently compared with 
the histologic results. The mean time 
interval between the gadoxetic acid–en-
hanced MR examination and surgery or 
biopsy of the lesion was 119.8 days 6 
4.3 (standard deviation) (range, 1 day 
to 4 months). Figure 1 is a flowchart of 
the excluded and included patients.
MR Examination Protocol
At both institutions, all MR examina-
tions were performed by using either 
a 3-T or 1.5-T imager (Magnetom Trio 
Tim or Magnetom Symphony Maestro 
Class; Siemens Healthcare, Erlangen, 
Germany) with the following sequences: 
T1-weighted in phase and opposed 
phase, respiratory-triggered T2-weight-
ed fat-suppressed turbo spin echo, and 
three-dimensional fat-suppressed gra-
dient-echo T1-weighted acquisitions. 
Dynamic gadoxetic acid–enhanced se-
quences were performed by using a 
bolus tracking system during the arte-
rial phase. The dose of contrast media 
was based on the weight of the patient 
(0.025 mmol/kg or 0.1 mL/kg, max-
imum of 10 mL) and was administered 
with a power injector (Medrad Spectris 
Solaris EP MR Injection System; Bayer 
Healthcare). The flow rate was 1 mL/sec, 
followed by a 200-mL saline solution flush 
(administered at 1 mL/sec). The portal 
venous (PV) and delayed phase images 
were then acquired at 70 and 300 sec-
onds, respectively. The HBP images were 
obtained 20 minutes after intravenous 
administration of gadoxetic acid. Table 1 
provides the examination parameters.
Image Evaluation
All MR images were retrospectively and 
independently reviewed on a commer-
cial picture archiving and communica-
tion system station (PACS version 5.2; 
Figure 1
Figure 1: Flowchart shows the excluded and included patients.
Agfa Health Care, Mortsel, Belgium) by 
two observers: a radiologist who spe-
cialized in abdominal MR imaging with 
more than 20 years of experience (A.B.) 
and a radiologist in her 5th year of 
training (N.B.). Both radiologists were 
blinded to the pathologic diagnosis and 
clinical data. Before interpreting the 
images, both radiologists met to set the 
criteria for the interpretation of all se-
quences of MR examinations. For train-
ing purposes, the two readers jointly 
reviewed 20 sample cases of pathologic 
analysis–confirmed HCAs, which were 
not included in this study. They decided 
to analyze the following: (a) the number 
of lesions; (b) the diameter of the lesion 
or lesions; (c) the location of the re-
sected or biopsied lesions on the basis 
of the Couinaud numbering system; (d) 
the contour of the nodules (ie, smooth 
or lobulated); (e) the signal intensity of 
the lesions on T1- and T2-weighted se-
quences compared with that of the sur-
rounding liver parenchyma scored as 
hypointense, isointense, moderately hy-
perintense, or markedly hyperintense 
(on T2-weighted images, the signal in-
tensity was considered markedly hyper-
intense if it was greater than or equal to 
spleen signal intensity); (f) the appear-
ance of the lesion on each sequence 
(ie, homogeneous or heterogeneous); 
(g) the presence of macroscopic hem-
orrhage, defined as focal T1- and T2-
weighted hyperintense and hypointense 
area, respectively; (h) the presence of 
a necrotic or cystic component, de-
fined as nonlinear high signal intensity 
on T2-weighted images, nonenhancing 
after contrast agent administration, 
and margins that are not sharp; (i) the 
presence of a central scar, defined as 
linear high- or low-signal-intensity area 
on T2-weighted images, enhancing af-
ter contrast agent administration in ar-
terial and PV phases, and washout in 
the HBP; (j) the presence of a pseu-
docapsule from compression of normal 
adjacent liver parenchyma, which was 
defined as a rim of high signal inten-
sity on T2-weighted images that en-
hances and retains contrast agent in 
all phases, including the HBP (if due 
to vaguely enlarged veins, it appears 
as a thin hypointense rim at the HBP); 
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(k) the presence of fat deposits in the 
lesion, defined as signal drop on op-
posed-phase T1-weighted MR images 
(absence, focal, or diffuse; mild or se-
vere); (l) the presence of steatosis in 
the nontumoral liver (mild, moderate 
or severe); (m) enhancement pattern 
in the arterial, PV, or delayed phase 
(homogeneous or heterogeneous), 
and (n) the intensity of enhancement 
(none; mild, less than PV; moderate, 
approximately equal to PV; or marked 
approximately equal to aorta). Fur-
thermore, contrast agent retention or 
washout in the PV, delayed phases, and 
HBP was documented.
Finally, from the MR imaging find-
ings evaluated, each radiologist was 
asked to make an a priori diagnosis 
for each lesion detected on the basis of 
typical features of those lesions, as pre-
viously published (2,4,11,13–17,25).
An inflammatory HCA was diag-
nosed if the lesion was moderately 
to markedly hyperintense at T2, with 
or without peripheral hyperintensity 
(pseudocapsule or atoll sign), and hy-
pointense at T1 without signal drop at 
chemical shift imaging, associated with 
intense arterial enhancement that per-
sisted in venous and delayed phases, 
and presence of steatosis in the non-
tumoral liver. A lesion with a thick hy-
perintense rim on T2-weighted images 
that showed enhancement in arterial 
and PV phases only, with washout on 
the HBP, was labeled as the atoll sign, 
rather than pseudocapsule. Otherwise, 
it was defined as having a pseudocap-
sule if it met the criteria defined above.
A steatotic HCA was diagnosed 
if the lesion showed signal loss at T1 
out-of-phase sequences compared with 
in-phase sequences, moderate arterial 
enhancement that did not persist into 
the venous and delayed phases, and 
moderately high T2 signal intensity.
A b-catenin HCA was diagnosed if the 
lesion was mainly heterogeneously hyper- 
and hypointense, respectively, on T2- and 
T1-weighted precontrast sequences, had 
a central scar, and had no signal loss at 
chemical shift imaging. On contrast-en-
hanced images, the lesion had to be (ho-
mogeneously or heterogeneously) hyper-
vascular in the arterial phase and show 
either persistence (signal intensity un-
changed or decreased but still present in 
the PV phase). In the delayed phase and 
HBP, lesion conspicuity was compared 
with that of the surrounding liver paren-
chyma (ie, relative washout) (18,26).
To our knowledge, no characteris-
tic MR imaging features have yet been 
proposed for unclassified HCAs (3,4). 
Therefore, all other HCAs without ste-
atosis and that did not fit the criteria 
for any other focal liver lesion were as-
signed unclassified.
Lastly, for each lesion, the reten-
tion or washout of gadoxetic acid in 
the HBP was compared with OATP 
and MRP expression. Finally, lesion 
features, enhancement patterns, and a 
priori diagnosis from both readers were 
compared with the final histopathologic 
diagnosis. The interreader agreement 
was calculated.
Histopathologic Analysis and 
Immunohistochemical Staining
To confirm the diagnosis, all HCA spec-
imens were reviewed again by two liver 
pathologists (J.S. and F.W., with 7 and 
20 years of experience, respectively) in 
consensus. The final histologic diagno-
sis of HCA was made according to the 
accepted criteria (6,8,27). To subtype 
the HCAs, immunohistochemical stains 
were applied to paraffin sections in-
cluding polyclonal antibody liver–fatty 
acid binding protein (1:100 dilution; 
Biotechnology, Santa Cruz, Calif), 
Table 1





Gap Matrix TR (msec) TE (msec) FOV (mm)
Sequence 1.5 T 3 T 1.5 T 3 T 1.5 T 3 T 1.5 T 3 T 1.5 T 3 T 1.5 T 3 T
In-phase T1-weighted GRE  
FLASH 2D 
6 5 2 1 256 3 192 320 3 240 100 130 2.27 2.46 380 350
Opposed-phase T1-weighted  
2D GRE FLASH 
6 5 2 1 256 3 192 320 3 240 100 131 5.19 3.69 380 350
Axial precontrast T1-weighted  
3D GRE VIBE SPAIR 
3–4 1.7 2 256 3 179 256 3 146 4.8 2.67 2.38 0.97 380 430
Axial postcontrast T1-weighted 3D  
GRE VIBE SPAIR* 
3–4 1.7 2 256 3 179 256 3 146 4.8 2.67 2.38 0.97 380 430
Axial T2-weighted fat-suppressed TSE 6 5 2 1 320 3 224 320 3 202 1550 2000 93 95 380 370
HBP axial postcontrast T1-weighted  
3D GRE VIBE SPAIR
3–4 1.7 2 256 3 179 256 3 146 4.8 2.67 2.38 0.97 380 430
Note.—2D = Two-dimensional, 3D = three-dimensional, FLASH = fast low angle shot, FOV = field of view, GRE = gradient echo, SPAIR = spectral attenuated inversion recovery, TE = echo time, 
TR = repetition time, TSE = turbo spin echo, VIBE = volumetric interpolated breath-hold examination.
* Sequence was performed three times: arterial, PV, and delayed.
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monoclonal antibody amyloid A (1:800 
dilution; Dako, Glostrup, Denmark), 
monoclonal antibody HSP70 (1:50 dilu-
tion; Biotechnology), glutamine synthe-
tase (1:100 dilution, Biocare Medical, 
Concord, Calif), and monoclonal anti-
body b-catenin (1:100 dilution; BD Bio-
sciences, San Jose, Calif) (23,24). The 
primary antibodies used (OATP1B1/3, 
MRP2, and MRP3) are listed in Table 
E1 (online) (28,29). HCAs were sub-
divided on the basis of the phenotypic 
classification by immunohistochemistry 
into steatotic, b-catenin, inflammatory, 
and unclassified subtypes (7,10). Im-
munohistochemical staining patterns 
and intensity of the HCAs relative to 
that of the adjacent liver parenchyma 
were compared. The expression of the 
transporter proteins was qualitatively 
assessed and compared with healthy 
liver by using a four-point scale: a grade 
of 0 indicated no expression; a grade 
of 1 indicated decreased expression 
relative to normal liver tissue; a grade 
of 2 indicated equivalent expression to 
normal liver tissue; and a grade of 3 
indicated increased expression relative 
to adjacent liver. Grading was based on 
the area of the nodule with the highest 
degree of expression.
Statistical Analysis
The statistical analysis was performed 
by using commercially available soft-
ware (MedCalc for Windows, version 
9.3.2.0, MedCalc Software, Mariaker-
ke, Belgium; and SPSS for Mac, version 
21.0, SPSS, Chicago, Ill).
Descriptive statistics were cal-
culated for clinical and imaging var-
iables by using median and range for 
continuous variables, and frequencies 
and percentages for categorical vari-
ables. Because of the high interreader 
agreement, receiver operating charac-
teristic curves were generated only for 
reader 1 to test the diagnostic perfor-
mance of MR imaging features. The re-
lationship between HBP appearance (ie, 
retention or washout), grade of trans-
porter expression, and HCA subtype 
was assessed by using Spearman rank 
correlation coefficient and Pearson x2 
test. Interreader agreement was calcu-
lated by using Cohen simple k statistic 
with 95% confidence intervals and  was 
interpreted as follows: 0–0.20, slight 
agreement; 0.21–0.40, fair agreement; 
0.41–0.60, moderate agreement; 0.61–
0.80, substantial agreement; and 0.81–
1.00, almost perfect agreement (30). P 




Twenty-nine patients with 43 histologic 
analysis–proven liver adenomas were 
included in this study. The majority of 
patients were women (23 of 29 patients 
[79%]) with a median age of 43 years 
(age range, 19–79 years). There were 
from one to 13 lesions per patient, with 
a medium tumor dimension of 38 mm 
(range, 5–125 mm). The histopatho-
logic analysis after lesion biopsy (eight 
patients and eight lesions) or surgery 
(21 patients and 35 lesions) diagnosed 
10 steatotic adenomas (25%), 21 inflam-
matory adenomas (49%), six b-catenin 
adenomas (13%), and six unclassified 
adenomas (13%). Sixteen of 29 pa-
tients (55%) had contributory clinical 
findings (Table 2; Table E2 [online]).
Imaging Characteristics and 
Enhancement Pattern
The lesion contour, signal intensity on 
T1- and T2-weighted images, and the 
presence of hepatic and lesion steato-
sis, pseudocapsule or atoll sign, central 
scar, hemorrhage, and/or necrosis and 
the dynamic enhancement pattern in 
the arterial, PV, and delayed postcon-
trast phases, and retention or washout 
of gadoxetic acid in the HBP (Figs 2, 3) 
are tabulated for inflammatory, stea-
totic, b-catenin, and unclassified liver 
adenomas (Table 3).
Expression of Transporter Proteins
The OATP1B1/3 transporter had a de-
creased expression in nine of 10 stea-
totic and six of six unclassified lesions 
and an equivalent-to-increased expres-
sion in 16 of 21 inflammatory and five of 
six b-catenin lesions (P , .001) (Table 
E2 [online]). OATP1B1/3 expression 
was the main agent responsible for 
uptake of gadoxetic acid in HCAs (P , 
.001) (Fig 4). OATP1B1/3 expression 
was significantly different between tu-
mors that showed washout and those 
that showed retention on HBP images. 
All tumors with equivocal or increased 
expression of OATP1B1/3 showed 
contrast agent retention on HBP im-
ages (11 of 11 images [100%]), while 
tumors that showed decreased or no 
expression of OATP1B1/3 tended to 
show gadoxetic acid washout on HBP 
images (21 of 32 images [66%]) (P , 
.001). There was a variable expression 
for MRP2 and MRP3 in the four types 
of liver adenomas (Table E2 [online]). 
Excretion was determined by MRP3 only 
(P = .003) (Fig 4); MRP2 appeared to 
Table 2
Demographics and Clinical Data
Parameter Data
No. of patients 29
Total no. of lesions 43
No. of men 6 (21)
No. of women 23 (79)
Type of liver adenoma
 Steatotic 10 (23)
 Inflammatory 21 (49)
 b-catenin 6 (14)
 Unclassified 6 (14)
No. of lesion biopsies 8 (19)
No. of surgeries 35 (81)
Clinical data of patients
 Metabolic syndrome 3 (10)
 Obesity 6 (21)
 Contraceptive or anabolic  
  steroid use
4 (14)
 Inflammatory syndrome 1 (3)
 Glycogen storage disease 3 (10)
 No underlying liver disease 12 (42)
Median continuous variables*
 Age at surgery or biopsy (y) 43 (19–79)
  Men† 49 (21–59)
  Women† 43 (19–79)
 Max tumor dimension (mm) 38 (5–125)
 No. of lesions 1 (1–13)
Note.—Data are numbers of patients or lesions unless 
otherwise indicated; data in parentheses are 
percentages unless otherwise indicated. There were 29 
patients and 43 lesions.
* Data in parentheses are range.
† P = .6 according to Mann-Whitney test for continuous 
variables.
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have no role (P = .345) (Fig 5). MRP3 
expression was significantly different be-
tween the two tumor groups that showed 
washout and retention on HBP images 
(Table 4). More specifically, all tumors 
that showed no expression or decreased 
expression of MRP3 showed contrast 
agent retention on HBP images (11 of 
11 images [100%]), while tumors that 
showed equivalent or increased expres-
sion of MRP3 tended to show contrast 
agent washout on HBP images (15 of 32 
images [47%]) (P = .008) (Table 4).
Diagnostic Accuracy
The interreader agreement for the in-
dividual MR imaging features ranged 
from substantial to almost perfect (k 
= 0.72–1), whereas the k value for the 
overall diagnostic performance was 
0.85 (Table 5). Because of this excellent 
agreement, the table lists the diagnostic 
findings of reader 1.
For the diagnosis of inflammatory 
adenoma, the area under the curve was 
0.79 (95% confidence interval: 0.64, 
0.90), sensitivity was 80.9% (17 of 21), 
specificity was 77.3% (17 of 22), pos-
itive predictive value was 77.3% (17 
of 22), and negative predictive value 
was 81% (17 of 21); for the steatotic 
type, the area under the curve was 
0.90 (95% confidence interval: 0.77, 
0.97), sensitivity was 80% (eight of 10), 
specificity was 100% (33 of 33), pos-
itive predictive value was 100% (eight 
of eight), and negative predictive value 
was 94.3% (33 of 35); and for the b-
catenin type, the area under the curve 
was 0.87 (95% confidence interval: 
0.74, 0.95), sensitivity was 83.3% (five 
of six), specificity was 91.9% (34 of 37), 
positive predictive value was 62.6% 
(five of eight), and negative predictive 
value was 97.1% (34 of 35). The area 
under the curve for the unclassified 
HCAs showed no statistical significance 
compared with chance (area under the 
curve, 0.62 [95% confidence interval: 
0.46, 0.76]; sensitivity, 33.3% [two of 
six]; specificity, 91.9% [34 of 37]; pos-
itive predictive value, 40.1% [two of 
five]; negative predictive value, 89.4% 
[34 of 38]; P = .33).
Discussion
The results of this study suggest a mech-
anistic explanation for the retention and 
washout of gadoxetic acid on HBP im-
ages of the HCA subtypes on the basis of 
the recent Bordeaux group classification 
(7,10). Our results, in which we used 
Figure 3
Figure 3: Images in a 24-year-old woman with metabolic syndrome. An encapsulated moderately hyperintense mass with a focal scar-like structure (arrow) on (a) 
axial T2-weighted baseline image and shows (b) dramatic increase on 2-year follow-up axial T2-weighted image and (c) inhomogeneous contrast-agent retention on 
gadoxetic acid–enhanced T1-weighted MR image during the HBP. Histologic analysis confirmed a 10-cm adenoma that stained positive for b-catenin.
Figure 2
Figure 2: MR images in a 46-year-old woman with inflammatory syndrome (ie, fever, leukocytosis, and elevated C-reactive protein). A 5-cm mass in the right liver 
lobe is a moderately hyperintense lesion (arrow) with a peripheral prominent hyperintense band (the so-called atoll sign) on (a) axial T2-weighted image, (b) it strongly 
enhanced during the arterial phase of gadoxetic acid–enhanced T1-weighted MR imaging, and (c) shows inhomogeneous contrast-agent retention during the HBP. 
Histologic analysis confirmed the diagnosis of inflammatory adenoma.
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Table 3














Opposed-phase T1 signal drop  
 in nontumoral liver
 Absent 6 (24) 8 (80) 6 (100) 5 (83)
 Present 15 (76) 2 (20) 0 (0) 1 (17)
Opposed-phase T1 signal loss  
 in the lesion
 Absent 17 (81) 2 (20) 5 (83) 6 (100)
 Mild 4 (19) 4 (40) 1 (17) 0 (0)
 Severe 0 (0) 4 (40) 0 (0) 0 (0)
 Diffuse 2 (9) 8 (80) 0 (0) 0 (0)
 Focal 2 (9) 0 (0) 1 (17) 0 (0)
Contour
 Lobulated 15 (71) 5 (50) 3 (50) 6 (100)
 Smooth 6 (29) 5 (50) 3 (50) 0 (0)
Atoll sign
 Absent 13 (62) 10 (100) 6 (100) 3 (50)
 Present 8 (38) 0 (0) 0 (0) 3 (50)
Pseudocapsule
 Absent 8 (38) 8 (80) 3 (50) 3 (50)
 Present 13 (62) 2 (20) 3 (50) 3 (50)
Central scar
 Absent 12 (57) 10 (100) 5 (83) 2 (33)
 Present 9 (43) 0 (0) 1 (17) 4 (67)
Hemorrhage
 Absent 21 (100) 10 (100) 4 (67) 6 (100)
 Present 0 (0) 0 (0) 2 (33) 0 (0)
Necrosis
 Absent 17 (81) 10 (100) 5 (83) 2 (33)
 Present 4 (19) 0 (0) 1 (17) 4 (67)
T2-weighted SI
 Hypo/isointense 4 (19) 7 (70) 0 (0) 1 (17)
 Moderately hyperintense 4 (19) 3 (30) 4 (67) 3 (50)
 Strongly hyperintense 13 (62) 0 (0) 2 (33) 2 (33)
T1-weighted precontrast SI 
 Hypointense 7 (34) 4 (40) 2 (33) 3 (50)
 Isointense 11 (52) 2 (20) 3 (50) 3 (50)
 Hyperintense 3 (14) 4 (40) 1 (17) 0 (0)
Postcontrast T1-weighted SI
 Arterial phase*
  Mild 0 (0) 1 (10) 0 (0) 0 (0)
  Moderate 3 (14) 8 (80) 4 (67) 4 (67)
  Severe 18 (86) 1 (10) 2 (33) 2 (33)
 PV phase
  Washout 1 (5) 7 (70) 2 (33) 1 (17)
  Persistence of contrast agent 20 (95) 3 (30) 4 (67) 5 (83)
 Delayed phase 300 sec
  Washout 11 (52) 8 (80) 5 (83) 1 (17)
  Persistence of contrast agent 10 (48) 2 (20) 1 (17) 5 (83)
Table 3 (continues)
gadoxetic acid, corroborated those of 
previous studies; the majority, or 32 of 
43 HCAs (75%), demonstrated wash-
out in the HBP (13,14,31). However, 
in our cohort, 11 of 43 (25%) HCAs 
retained gadoxetic acid and appeared 
inhomogeneously isointense to hyper-
intense on the HBP images. By ana-
lyzing our results in detail, we found 
that retention of gadoxetic acid in the 
HBP was shown in six of 21 inflamma-
tory adenomas, five of six b-catenin 
adenomas, but none of the 10 stea-
totic HCAs and none of the six unclas-
sified HCAs. These results again are 
in accordance with recent reports in 
the literature (15–17). The retention 
of gadoxetic acid in the HBP appears 
first quite logical because adenomas, 
like focal nodular hyperplasia, are con-
sidered as cholestatic lesions (ie, they 
have a limited ability to excrete this 
hepatobiliary contrast agent because 
of altered cell structure or blind-ending 
biliary ductules) (17,25). Even so, the 
majority of HCAs did show washout in 
the HBP, which suggests that hepato-
cellular uptake and excretion of gadox-
etic acid is not simply because of the 
abnormal anatomic connection to the 
biliary tree, and it may be more depen-
dent on the expression of the hepatic 
transporters. By using semiquantita-
tive immunohistochemistry, we set out 
to confirm this hypothesis (24). It is 
well known that gadoxetic acid move-
ment in hepatocytes is mediated by 
various transporters located on either 
the sinusoidal (OATP1B1/3 and MRP3) 
or canalicular (MRP2) membranes of 
the cell (19,22,32). Gadoxetic acid en-
ters the hepatocytes via active trans-
port by OATP1B1/3 and is excreted 
into the biliary tree via MRP2 (23,28). 
Organic acid efflux from hepatocytes 
may also occur through the sinusoidal 
membrane because of bidirectional 
transport with OATP1B1/3 and MRP3 
(23,28). We found that OATP1B1/3 ex-
pression was the main determinant re-
sponsible for uptake of gadoxetic acid 
in HCAs (P , .001). Furthermore, ex-
cretion was determined by MRP3 only 
(P = .003). In general, the degree of 
OATP and MRP3 expression corre-
lated with gadoxetic acid retention and 
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washout, respectively. MRP2 appeared 
to have no significant role in the chole-
static feature of HCAs (P = .345).
Furthermore, our MR diagnostic 
accuracy is similar to those reported 
in previous publications (13–16,33); 
we found that the majority of steatotic 
and inflammatory HCAs demonstrated 
the classic morphologic features at T2 
and precontrast T1 sequences and dy-
namic (ie, arterial and PV phases) en-
hancement pattern by using gadoxetic 
acid, which is similar to those reported 
that use gadolinium chelates (1,11,12). 
However, two steatotic HCAs showed no 
signal loss at opposed-phase sequences 
and were misclassified as inflammatory 
HCAs. Two inflammatory HCAs were 
classified correctly despite signal loss 
at the opposed-phase sequence because 
the other features fit to this subtype. 
For the b-catenin type, we achieved very 
good sensitivity and specificity by using 
the presence of a central scar, hyperin-
tense signal on T2-weighted images, and 
persistence of contrast on the PV and 
delayed phases (11,16).
Interestingly, most (five of six 
[83%]) b-catenin and 29% (six of 21) 
inflammatory HCAs mimicked focal 
nodular hyperplasia (ie, showed ga-
doxetic acid retention in HBP), which 
can pose a diagnostic dilemma (34). 
Whereas focal nodular hyperplasia re-
quires neither follow-up nor treatment, 
inflammatory and b-catenin HCAs re-
quire intervention. Fortunately, 90% 
of focal nodular hyperplasia undergo 
homogeneous gadoxetic retention in 
the HBP series in contrast to the het-
erogeneous retention pattern of inflam-
matory and b-catenin HCAs, which we 
found in our cohort as well (13,15,26). 
In addition, the higher T2-weighted sig-
nal intensity may favor the diagnosis 
of an adenoma (17,26). Furthermore, 
clinical risk factors can be useful to de-
termine which of these lesions should, 
at least, be followed up (17). Eighty-five 
percent (17 of 20) of our patients with 
inflammatory and/or b-catenin HCA 
were obese or had metabolic syndrome, 
systemic inflammatory syndrome, and/
or glycogen storage disease, and/or 
used oral contraceptives or steroids.
Although there are still no accepted 
guidelines for adenoma management, 
steatotic, unclassified, and inflamma-
tory HCAs can be followed up if the le-
sions do not exceed 5 cm in diameter 
and do not grow (35). Surgical removal 
is indicated if any growth occurs (10). 
In the case of b-catenin HCAs, surgery 
is needed, independent of size (10,35).
Our study has several limitations. 
First, the total number of isointense or 
hyperintense HCAs on HBP examined 
was small because such tumors are rel-
atively rare. However, we believe that 
the data obtained are sufficient to make 
some observations about the molecu-
lar biology of gadoxetic acid–enhanced 
MR imaging pharmacodynamics in the 
subtypes of HCAs. Rarer still are the 
b-catenin HCAs. Therefore, results that 
pertain to these lesions should be con-
sidered with caution.
Second, we showed that OATP1B1/3 
and MRP3 expression correlated well 
with the enhancement patterns in the 
majority of HCAs. However, these re-
sults should be interpreted with caution 
because nonanionic and other organic 
cation transporters also participate in 
the uptake and washout of gadoxetic 
acid (32). As well, there may be genetic 
polymorphism among OATP trans-
porters, which explains why there was 
a mismatch between transporter ex-
pression and the gadoxetic acid pattern 
in HBP in the remaining HCAs (19). 
Next, only part of our histopathologic 
specimens was en bloc resections. The 
remainder were biopsy specimens and 
Figure 4
Figure 4: (a) Image shows immunohistochemistry with OATP1B1/3-specific stain. The brown cells indicate 
an overexpression of OATP1B/3 (OATP expression grade 3 [ie, increased expression relative to adjacent liver] 
adenoma; arrows) on the sinusoidal side in the inflammatory adenoma (shown in Fig 2) (original magnifi-
cation, 3400). (b) Image shows immunohistochemistry with MRP3-specific stain. The linear rust-colored 
bands demarcate areas of MRP3 overexpression (arrows) on the canalicular side in an inflammatory grade 3 














 HBP 20 min
  Washout 15 (71) 10 (100) 6 (100) 1 (17)
  Retention 6 (29) 0 (0) 0 (0) 5 (83)
Note.—Data are number of lesions; data in parentheses are percentages. SI = signal intensity.
* The intensity of enhancement was defined as none, mild if less than PV, moderate if approximately equal to PV, or marked if 
approximately equal to aorta. Washout and retention is defined according to adjacent liver parenchyma.
Table 3 (continued)
Imaging Features of Liver Adenoma Lesions for Reader 1
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Figure 5
Figure 5: Diagram of the relationship between the OATP1B1/3 and MRP3 regarding retention or washout of 
gadoxetic acid in the HBP. MRP2 appeared to have no substantial role, perhaps because of the absence of any 
connection to the bile ducts. The gray arrows indicate no function; the black arrows indicate full function. The wavy 
lines are no excretion because of the lack of connection to the bile ducts and the dots are absence of transporters.
imaging in differentiating subtypes of 
HCAs because the readers were aware 
that the diagnosis must be some type 
of HCA. In clinical practice, we would 
have to differentiate not only from its 
HCA subtype, but also focal nodular hy-
perplasia or hepatocellular carcinoma 
in noncirrhotic livers. However, patient 
demographics (ie, age, sex, and clinical 
risk factors) favor one diagnosis over 
the others. Nevertheless, the near-per-
fect interobserver agreement confirms 
the ability of this technique to suggest 
the correct a priori classification of 
HCAs.
In conclusion, gadoxetic acid–en-
hanced MR imaging can favor the di-
agnosis of a specific type of HCA. 
Furthermore, the degree of OATP and 
MRP3 expression correlated with ga-
doxetic acid retention and washout, 
respectively, in the HBP. A prospective 
multicenter study is necessary to verify 
these promising results.
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Arterial phase enhancement 0.81 .2 0.004 .9 0.13 .3
PV phase 0.34 .02 20.09 .5 20.18 .2
Delayed phase 5 min 0.38 .01 20.12 .4 20.62 ,.001
HBP 20 min 0.79 ,.001 20.13 .38 20.57 ,.001
Note.—The transporters only affected delayed and HBP phases. The degree of OATP and MRP3 expression correlated with 
gadoxetic acid retention and washout, respectively, in the HBP. MRP2 appeared to have no role.
Table 5
Interreader Agreement
Imaging Features k Value







T2-weighted lesion signal intensity 0.86
T1-weighted lesion signal intensity 0.94
Arterial phase enhancement 0.96
PV phase, 70 sec 0.80
Delayed phase, 5 min 0.86
HBP, 20 min 0.94
Final radiologic diagnosis 0.85
Note.—Forty-three lesions were used for each 
parameter.
thus subject to sampling error. There-
fore, the degree of expression of trans-
porter proteins might not have been 
correctly graded in biopsy specimens, 
especially in heterogeneous lesions. 
One other limitation of this study is the 
overestimation of the diagnostic perfor-
mance of gadoxetic acid–enhanced MR 
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